
FDA approves twice-a-year injection for HIV prevention
Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo. In clinical trials, the drug was found to dramatically reduce the risk of infection and provide near-total protection against HIV, significantly more than the primary options available for pre-exposure prophylaxis or PrEP.
Therapies called PrEP have been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting shots, such as injections every two months of the medication Apretude. But a twice-yearly shot of lenacapavir has now become another option in the prevention toolbox – making it the first and only such shot for HIV prevention.
'Yeztugo could be the transformative PrEP option we've been waiting for – offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,' Dr. Carlos del Rio, a distinguished professor of medicine in the Division of Infectious Diseases at Emory University School of Medicine and co-director of the Emory Center for AIDS Research, said in a Gilead news release. 'A twice-yearly injection could greatly address key barriers like adherence and stigma, which individuals on more frequent PrEP dosing regimens, especially daily oral PrEP, can face. We also know that, in research, many people who need or want PrEP preferred less frequent dosing.'
With any PrEP drug, 'by having that medicine in your bloodstream or in your body, if you encounter HIV, it blocks it from taking hold. It arrests infection from taking hold,' said Dr. Jared Baeten, senior vice president of clinical development and the virology therapeutic area head at Gilead Sciences.
The human immunodeficiency virus or HIV, spread primarily through unprotected sex or sharing needles, attacks the body's immune system, and without treatment, it can lead to acquired immunodeficiency syndrome or AIDS. Although rates of new HIV infections have fallen in the US, about 1.2 million people are estimated to have HIV, and about 13% of them may not know it.
A study called the PURPOSE 2 trial found that just two shots a year of lenacapavir can reduce the risk of HIV infection by 96%, proving it to offer near-total protection against HIV. Another study, the PURPOSE 1 trial, found that lenacapavir demonstrated 100% efficacy for HIV prevention in women.
'Lenacapavir is a unique option for people for HIV prevention because it's an injection given just twice a year. So people can get it privately, discreetly, and then set it and forget it and not have to think about it until six months later,' Baeten said. 'For many people, that might be the empowered, private option that might make HIV prevention workable in their lives.'
There continues to be a lot of stigma, fear and misinformation around HIV, said Ian Haddock, who participated in the PURPOSE 2 trial for lenacapavir.
When Haddock was a teenager living in rural Texas, he recalled, he faced some of that stigma.
'The first thing that was said when my family found out that I was queer was, 'You're going to get AIDS,' ' said Haddock, who does not live with HIV. 'So that's the first thing I heard.'
Now, at 37, Haddock knows that HIV does not discriminate. He works to break such misguided stereotypes about the LGBTQ+ community as the founder of a nonprofit called the Normal Anomaly Initiative, and he said he is proud to have participated in the clinical trial.
'It feels like a full-circle moment,' he said.
Haddock said he started to take daily PrEP pills in 2015 to help reduce his risk of HIV, but sometimes they would give him an upset stomach or he would forget to take them.
In January 2024, when he learned about the lenacapavir clinical trial, he quickly enrolled. He had no side effects during the trial other than irritation at the injection site, he said.
Even though the trial has concluded, Haddock said, he plans to continue receiving lenacapavir injections twice a year, and he hopes the FDA approval will help raise awareness of HIV prevention tools.
In 2012, the FDA approved Truvada, also made by Gilead Sciences, making it the first PrEP medication for HIV prevention in uninfected adults in the United States – but 'even though PrEP has been around since 2012, people don't really know what it is, and they often kind of conflate it to having HIV or being extremely promiscuous,' Haddock said.
'So this just opens up a completely new opportunity,' he said of lenacapavir.
Last year, Gilead Sciences released data from the PURPOSE 2 trial that showed 99.9% of the participants who received an injection of lenacapavir twice a year for HIV prevention did not become infected.
There were only two cases among 2,180 people, effectively proving 89% more effective than the PrEP pill Truvada. The trial was unblinded early because it met its key endpoints, allowing lenacapavir to be offered to all participants, and the drug was found to be well-tolerated.
'The most common side effects, as you might expect, are injection-site reactions,' Baeten said, such as rash or discomfort.
The PURPOSE 2 trial included cisgender men, transgender men, transgender women and nonbinary people 16 or older who had sex with partners assigned male at birth. Some of the study participants became pregnant during the trial and continued to receive lenacapavir during pregnancy without complications, Baeten said.
'This is a milestone moment in the decades-long fight against HIV. With twice-yearly administration and remarkable efficacy, lenacapavir will help us prevent HIV on a scale never seen before,' Daniel O'Day, chairman and chief executive officer at Gilead Sciences, said in an emailed statement.
'After 17 years of research and pioneering clinical trials, Gilead scientists have delivered the next frontier in HIV innovation: a prevention medicine with remarkable efficacy that only needs to be delivered twice a year,' O'Day said. 'It's a true scientific breakthrough that could help millions of people around the world.'
Now that lenacapavir has been approved for prevention, people should be able to visit their providers and ask about the drug within two days, Gilead Sciences said in an email. The company added that it could take up to two months for someone to receive their first injections, based on coverage decisions.
The list price for lenacapavir, when used for HIV prevention, will be announced soon, Baeten said. The list price is expected to be different from when lenacapavir is used for the treatment of multidrug-resistant HIV, in which other HIV medications have not worked and the patient meets certain other requirements for lenacapavir treatment.
One study published in November in the Journal of Antimicrobial Chemotherapy found that for treatment, lenacapavir costs up to nearly $45,000 per person per year without insurance, as an average wholesale list price – but it could be mass-produced for less than $100 per person per year.
The team of researchers behind the study projected a possible minimum price based on the drug's current ingredients, production models and cost models. They demonstrated that lenacapavir could be mass-produced for up to $93 per person per year, potentially falling to about $40 per person per year 'if voluntary licences are in place and competition between generic suppliers substantially improves.'
'Voluntary licensing and multiple suppliers are required to achieve these low prices,' the researchers wrote in the study abstract. 'This mechanism is already in place for other antiretrovirals.'
Lenacapavir is the latest HIV prevention shot to receive FDA approval. Apretude, made by GSK's ViiV Healthcare, was the first injectable pre-exposure prophylaxis medication to receive approval in the US in 2021.
The hope is that PrEP tools could lead to a total halt to new HIV infections in future generations, Baeten said.
'Every one of us would like nothing more than to end this epidemic, and that's what really solid prevention can do for us – that coupled with testing and treatment,' he said.
'I want this next generation to think about HIV as something that they can end in their lifetime, end in their generation. And I want their next generation to be one where they've never had to think about HIV at all,' he said. 'We've got this amazing opportune moment right now as a world to think about where we can be in the future. We can be a world without HIV.'
The new FDA approval comes as the Trump administration has cut back funding for HIV-related research grants, HIV prevention and surveillance programs through the US Centers for Disease Control and Prevention, and sharply curtailed global HIV efforts.
The administration's 2026 budget proposal includes the elimination of funding for HIV programs, totaling more than $1.5 billion, according to the HIV+Hepatitis Policy Institute.
With the approval of lenacapavir for PrEP, 'now is not the time to pull the rug out from under HIV prevention,' Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, said in an email.
'The obliteration of CDC HIV prevention and surveillance programs is an absurd proposal that will just increase HIV infections and health costs down the road,' he said. 'We urgently call on Congress to reject these cuts in order to ensure that states and community-based organizations have the resources to prevent HIV, which is still a serious infectious disease and results in about 32,000 new cases each year.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
2 hours ago
- Medscape
Decline of Nonrecommended HIV Care in Medicare
TOPLINE: Among Medicare beneficiaries with HIV, the proportion receiving at least one nonrecommended antiviral prescription decreased substantially from 5.1% in 2013 to 0.1% in 2021. METHODOLOGY: Clinical guidelines in 2017 recommended discontinuing older, more toxic antivirals in people with HIV. However, some people continue to take them due to several barriers to switching. This cross-sectional study used a 20% random sample of traditional Medicare beneficiaries with Part-D coverage from 2013 to 2021 and categorized prescribed antivirals as nonrecommended — based on drug toxicity and the availability of more effective alternatives — the remaining being classified as preferred. The analysis examined the proportion of beneficiaries with HIV who received at least one nonrecommended antiviral vs those who received only preferred antivirals. TAKEAWAY: Of the total Medicare beneficiaries with HIV, 1052 (74.1% aged < 65 years; 74.9% men) received at least one nonrecommended antiviral prescription, and 28,019 (75.9% aged < 65 years; 74.4% men) received only preferred antivirals. Compared with beneficiaries who received only preferred antivirals, those who received nonrecommended antivirals were more likely to be from the South (45.6% vs 50.5%; standardized mean difference, 0.10). Didanosine and nelfinavir emerged as the most frequently prescribed nonrecommended antivirals, accounting for 27.5% and 25.3% of prescriptions, respectively. The proportion of beneficiaries receiving nonrecommended antivirals substantially declined from 5.1% in 2013 to 0.1% in 2021. IN PRACTICE: 'Further research should assess how many beneficiaries switched to less toxic antivirals over time (rather than being censored), characteristics associated with switching to safer alternatives, alternative antivirals prescribed instead, and how more recent ART [antiretroviral therapy] guideline recommendations may influence future prescription patterns,' the authors wrote. SOURCE: This study was led by Jose F. Figueroa, MD, Harvard T.H. Chan School of Public Health, Boston. It was published online on May 1, 2025, in JAMA Network Open. LIMITATIONS: The study focused exclusively on traditional Medicare beneficiaries living with HIV, possibly limiting the generalizability of the findings to individuals with HIV covered by commercial insurance, Medicaid, or Medicare Advantage plans. HIV diagnoses relied on claims data. DISCLOSURES: This study was supported by grants from the National Institute on Aging, the Harvard Center for AIDS Research, and the Advancing Clinical Therapeutics Globally program. Some authors reported having financial ties with multiple foundations and pharmaceutical organizations. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


CBS News
7 hours ago
- CBS News
Bay Area man living with HIV concerned about federal cuts to medical funding
As the federal government moves forward with steep cuts to medical and research funding, some in the Bay Area who depend on that money are concerned about the future. But California lawmakers are trying to help. On Tuesday, Governor Gavin Newsom signed a budget allocating $75 million to support HIV services in the state. Paul Aguliar has been surviving with HIV for 37 years. He lives at Marty's Place in San Francisco. A housing co-op for low-income people living with HIV/AIDS in San Francisco. "It's a place where we live with HIV; we don't die from AIDs," said Aguilar. When he was diagnosed, he never thought he would come this far. "When you're told at the age of 25 that you have five years to live you had better clean up your life and do whatever you have to do, that's really frightening," Aguilar said, remembering his diagnosis. Advancements in HIV treatment allowed him to celebrate his 62nd birthday in June. But he's worried with HIV prevention and research cuts, some other people won't be as lucky. "It's really scary," Aguilar said. "It's like we're throwing back to 40 years ago. You're going to see an epidemic the likes of which is going to be even worse than what I walked through because you're going to see medically resistant strains, super strains and there's no scientific research being done on how to address this." President Donald Trump's FY26 budget proposes significant cuts in CDC-funded HIV prevention, testing and research. Governor Gavin Newsom and state legislators are trying to combat that with a budget that allocates $75 million to HIV and STI services. Jonathan Frochtzwajg with the San Francisco AIDs Foundation says $1 million is for hepatitis C testing equipment and $9 million is for public health workers who do contact tracing for HIV, the rest acts as protection. "The bulk of the money is $65 million in a contingency fund that the state can tap into if the federal government cuts dollars for critical HIV services, everything from prevention to care to housing," Frochtzwajg explained. He said prevention efforts are vital, as California sees 5,000 new HIV cases each year. "We know what prevents HIV transmission," said Frochtzwajg. "We have those tools. It's things like low-barrier HIV testing. It's things like distributing safer sex supplies. Helping folks get on Prep. Those tools we need funding for." Aguilar was cautiously optimistic about the funds. "75 million is not enough," Aguilar stated. "We definitely need more, We'll take what we can get." As of 2025, life expectancy for people living with HIV who are diagnosed early and receive treatment is nearly the same as the general population.


The Hill
17 hours ago
- The Hill
USAID cuts could result in 14M additional deaths: Research
A study published Monday found that the closure of the U.S. Agency for International Development (USAID) could result in more than 14 million additional deaths globally by 2030, including 4.5 million deaths of children younger than 5 years. The findings were released hours before Secretary of State Marco Rubio said the agency would officially shut down following President Trump's executive order earlier this year aiming to dismantle the agency. Many of the deaths are expected to occur in the African countries of Nigeria and Uganda due to the loss of funding for maternal and child health aid, in addition to epidemic and emerging disease surveillance. Researchers found that those two countries would contribute to 107,000 additional deaths globally in just one year of a disrupted malaria-control supply chain. The end of USAID pulls funding from non-governmental organizations including the UN World Food Programme, which closed its southern Africa office, placing 27 million people at risk of hunger amid the country's worst drought in decades, the study says. Former Presidents Obama and Bush have been critical of the Trump administration for the USAID closure, which also threatens to scale back America's role in the global fight against HIV and AIDS. 'Gutting USAID is a travesty, and it's a tragedy. Because it's some of the most important work happening anywhere in the world,' Obama said, according to The Associated Press. Rubio on Tuesday defended the shuttering of USAID, arguing the agency's objectives were often left unmet. 'Development objectives have rarely been met, instability has often worsened, and anti-American sentiment has only grown,' Rubio wrote in a blog post on Tuesday. 'This era of government-sanctioned inefficiency has officially come to an end.' The Monday study found that USAID-supported efforts have helped to prevent more than 91 million deaths across all age groups, including 30 million deaths among children. It said high levels of USAID funding were associated with a 15 percent reduction in mortality across all ages, a 65 percent reduction in mortality from HIV/AIDS, a 51 percent reduction from malaria, and a 50 percent reduction from neglected tropical diseases. In 2022, USAID was responsible for more than half of nutrition interventions, food distribution and agricultural interventions globally. 'Therefore, the impact of USAID on health and mortality reduction extends beyond its direct funding of health programmes and interventions,' the study's authors wrote. 'In particular, USAID's support for poverty alleviation, education, and water and sanitation interventions—among many others—might have had a substantial effect on health outcomes, also considering the broader spillover effects these interventions can have on entire communities,' it added. 'Indeed, poverty alleviation interventions alone have demonstrated important effects on reducing both adult and child mortality.' The research was funded by the Spanish Ministry of Science and Innovation, UK Medical Research Council and EU Horizon Europe.